62,292 Shares in Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Acquired by J.W. Cole Advisors Inc.

J.W. Cole Advisors Inc. bought a new position in Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund bought 62,292 shares of the biotechnology company’s stock, valued at approximately $506,000.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. China Universal Asset Management Co. Ltd. lifted its holdings in shares of Iovance Biotherapeutics by 116.0% during the third quarter. China Universal Asset Management Co. Ltd. now owns 6,356 shares of the biotechnology company’s stock worth $29,000 after buying an additional 3,414 shares during the last quarter. Annandale Capital LLC acquired a new position in shares of Iovance Biotherapeutics during the third quarter worth approximately $32,000. Clear Street Markets LLC acquired a new position in shares of Iovance Biotherapeutics during the third quarter worth approximately $35,000. AE Wealth Management LLC acquired a new position in shares of Iovance Biotherapeutics during the third quarter worth approximately $48,000. Finally, Pathstone Family Office LLC acquired a new position in shares of Iovance Biotherapeutics during the third quarter worth approximately $48,000. 77.03% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity

In other Iovance Biotherapeutics news, Director Merrill A. Mcpeak bought 250,000 shares of the stock in a transaction dated Tuesday, February 20th. The stock was bought at an average cost of $9.15 per share, for a total transaction of $2,287,500.00. Following the completion of the purchase, the director now owns 320,150 shares in the company, valued at approximately $2,929,372.50. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 10.40% of the stock is currently owned by corporate insiders.

Wall Street Analyst Weigh In

A number of research analysts have recently commented on the company. StockNews.com upgraded Iovance Biotherapeutics to a “sell” rating in a report on Friday, February 2nd. HC Wainwright restated a “buy” rating and issued a $32.00 target price on shares of Iovance Biotherapeutics in a research note on Thursday, February 29th. Piper Sandler upped their target price on Iovance Biotherapeutics from $18.00 to $19.00 and gave the company an “overweight” rating in a research note on Thursday, March 14th. Chardan Capital upped their target price on Iovance Biotherapeutics from $29.00 to $34.00 and gave the company a “buy” rating in a research note on Tuesday, February 20th. Finally, JMP Securities upped their target price on Iovance Biotherapeutics from $18.00 to $25.00 and gave the company a “market outperform” rating in a research note on Tuesday, February 20th. One investment analyst has rated the stock with a sell rating and ten have assigned a buy rating to the stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $24.64.

Iovance Biotherapeutics Price Performance

Iovance Biotherapeutics stock opened at $11.86 on Wednesday. The stock has a fifty day moving average price of $13.90 and a two-hundred day moving average price of $9.02. Iovance Biotherapeutics, Inc. has a 52-week low of $3.21 and a 52-week high of $18.33. The firm has a market capitalization of $3.31 billion, a P/E ratio of -6.31 and a beta of 0.62.

Iovance Biotherapeutics (NASDAQ:IOVA) last released its quarterly earnings data on Wednesday, February 28th. The biotechnology company reported ($0.45) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.44) by ($0.01). The business had revenue of $0.48 million during the quarter, compared to analysts’ expectations of $1.44 million. During the same period in the prior year, the company earned ($0.64) EPS. On average, equities research analysts predict that Iovance Biotherapeutics, Inc. will post -1.4 EPS for the current fiscal year.

Iovance Biotherapeutics Profile

Iovance Biotherapeutics, Inc, a commercial-stage biotechnology company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic melanoma and other solid tumor cancers in the United States. The company offers Amtagvi, a tumor-derived autologous T cell immunotherapy used to treat adult patients with unresectable or metastatic melanoma; and Proleukin, an interleukin-2 product for the treatment of patients with metastatic renal cell carcinoma.